TCTMD
@tctmd.bsky.social
930 followers 110 following 1K posts
Your source for breaking news, topical videos, and slides covering cardiovascular disease and interventions. Register at http://tctmd.com
Posts Media Videos Starter Packs
tctmd.bsky.social
Get a sneak peak of what to expect at #TCT2025 in San Francisco with Roxana Mehran, Juan Granada, and Martin Leon. Listen to the full episode of Rox Heart Radio now: www.tctmd.com/audio/rox-he...
Reposted by TCTMD
crfheart.bsky.social
👟 #TCTWhiteSneakerDay is back by popular demand!

Pack your favorite white kicks and get ready to step into a day of next-gen technologies, live cases, and groundbreaking science at #TCT2025

https://ow.ly/W1Zo50Xa6o7

#CardioSky #MedSky
tctmd.bsky.social
Type 1 MIs continue to be the most common, but the rate of type 2 MIs is on the rise. Compared with type 1, type 2 MIs have worse long-term outcomes, and there is a dearth of evidence-based therapies for their treatment. www.tctmd.com/news/type-2-...
Type 2 MI Diagnoses on the Rise, but Best Course of Action Unknown
With a mix of causes and comorbidities, type 2 MI patients do better than type 1 early on, then face worse long-term outcomes.
www.tctmd.com
Reposted by TCTMD
crfheart.bsky.social
10 days out. One epic experience ahead!

#TCT2025 is where the future of cardiovascular care takes shape. Let’s go! 💥 https://ow.ly/rFRu50X6FGR

#CardioSky #MedSky
Reposted by TCTMD
crfheart.bsky.social
🔮The future of #interventionalcardiology starts at #TCT2025

Get a front-row seat to breakthrough #innovation — from emerging technologies and pioneering techniques to a deep dive into #AI in health care.

Explore the possibilities! https://ow.ly/5KV350XaNHq

#CardioSky #MedSky
tctmd.bsky.social
Patients receiving specialized care after being discharged from an acute HF hospitalization have better long-term outcomes compared to those who don't, based on data from the UK. More here: www.tctmd.com/news/after-a...
After Acute HF Admission, Specialist Care Tied to Better Long-term Outcomes
The association was seen across the LVEF range—researchers say all patients should be offered this support.
www.tctmd.com
Reposted by TCTMD
crfheart.bsky.social
Late-breaking clinical trials & science at #TCT2025 will redefine the future of patient care. 🌍 From breakthrough data to global impact, this is where the most anticipated research takes center stage!

🎯 Be there for the discoveries that will shape tomorrow! https://ow.ly/8F9250XacNp

#CardioSky
tctmd.bsky.social
Fewer than one-quarter of HFrEF patients are on guideline-directed medical therapy in the VA system. Hurdles to quadruple therapy include high drug costs, fragmented healthcare, transient contraindications, and limited clinician knowledge. www.tctmd.com/news/too-few...
Too Few HF Patients on Guideline-Directed Medical Therapy in VA System
Costs aren’t the only barrier to achieving optimal medication adherence, the data indicate.
www.tctmd.com
Reposted by TCTMD
crfheart.bsky.social
🌍 Experience the energy of #TCT2025 from anywhere — for FREE!

The TCT World Connect Livestream brings you front-row access to select high-impact sessions led by world-renowned experts. Don’t miss this global gateway to groundbreaking science and bold ideas!

https://ow.ly/ig9N50Xa5R8

#CardioSky
tctmd.bsky.social
Novel GDF-15, a biomarker of oxidative stress and inflammation, may help predict adverse outcomes for patients with suspected ACS, according to new data. Findings indicate that cytokine may aid in the decision to send patients home from the ED or admit them. www.tctmd.com/news/novel-b...
Novel Biomarker GDF-15 Helps Risk-Stratify Patients With Suspected ACS
As a complement to other biomarkers, the cytokine may aid in the decision to send patients home from the ED or admit them.
www.tctmd.com
Reposted by TCTMD
crfheart.bsky.social
✨ AI is changing everything, and healthcare is no exception. Join us for a visionary #TCT2025 keynote address as Dr. Robert Wachter shares bold insights from his new book “A Giant Leap.” Discover what AI means for the future of medicine & how you can navigate this new era! https://ow.ly/BCge50X9Yi5
tctmd.bsky.social
The PCSK9 inhibitor evolocumab reduces the risk of MACE better than standard therapy alone in people with no previous history of CV events, based on data from the VESALIUS-CV trial. Read more here: www.tctmd.com/news/evolocu...
Evolocumab Wins for Primary Prevention in VESALIUS-CV
The 12,000-patient trial of the PCSK9 inhibitor met its primary endpoints in high-risk individuals with no prior CV events.
www.tctmd.com
tctmd.bsky.social
Juan Granada discusses potential pharmacologic therapies that may impact the progression of aortic stenosis with Marc Dweck in the latest episode of Heart Valve Matters. www.tctmd.com/audio/medica...
Reposted by TCTMD
crfheart.bsky.social
💡 Want a front-row seat to cutting-edge research? Join Dr. Timothy Henry on 10/28 when he reveals findings from a multicenter registry examining AI-enabled ECG interpretation in STEMI.

🔍 Don’t miss the full lineup of late-breaking trials & science! www.tctconference.com/late-breakin...

#CardioSky
Reposted by TCTMD
crfheart.bsky.social
#Innovation that matters. #TCT2025 brings together the science, strategy, and global collaboration to transform heart care.

Don’t miss your chance to be part of it all! www.tctconference.com/register

#CardioSky